Prospectus relating to Active Biotech's rights issue published
November 18 2016 - 09:15AM
2016-11-18
NOT FOR
RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR
INTO THE UNITED STATES, AUSTRALIA, JAPAN OR CANADA OR IN ANY OTHER
JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD
BE UNLAWFUL.
The prospectus relating to Active Biotech AB's
(publ) rights issue has now been published and is available on the
company's website, www.activebiotech.com. The prospectus can also
be ordered from Active Biotech by telephone +46 (0)46 19 20 00.
For further information, please
contact:
Tomas Leanderson, CEO
Tel: +46 (0)46 19 20 95
E-mail: tomas.leanderson@activebiotech.com
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
E-mail: hans.kolam@activebiotech.com
Active Biotech
AB
P.O. Box 724, SE-220 07 Lund, Sweden
Phone +46 (0)46 19 20 00
Fax +46 (0)46 19 11 05
Active Biotech AB (publ) (NASDAQ
Stockholm: ACTI) is a biotechnology company with focus on
neurodegenerative/inflammatory diseases and cancer. Laquinimod, an
orally administered small molecule with unique immunomodulatory
properties, is in pivotal Phase 3 development for the treatment of
relapsing remitting multiple sclerosis. Also, laquinimod is in
Phase 2 development for the treatment of primary progressive
multiple sclerosis and Huntington's disease. Furthermore,
commercial activities are conducted for the tasquinimod, paquinimod
och SILC projects. Please visit www.activebiotech.com for more
information.
Important information
This press release is not an offer to subscribe for shares in
Active Biotech and investors should not subscribe for or purchase
any securities, except on the basis of information provided in the
prospectus.
This press release may
not be made public, released or distributed, directly or
indirectly, in or into the United States, Australia, Japan or
Canada or in any other jurisdiction in which the distribution of
this press release would be unlawful. Further, this press release
does not constitute an offer to sell new shares, interim shares
("BTA") or subscription rights to any person in any jurisdiction in
which it is unlawful to make such offer to such person or where
such action would require additional prospectuses, registration or
other measures other than those pursuant to Swedish law. The
prospectus, application form and other documents associated with
the rights issue may not be distributed in or to any country where
such distribution or the rights issue would require such measures
set forth in the preceding sentence or be in violation of the
regulations of such country.
The new shares and
subscription rights have not been recommended or approved by any
United States federal or state securities commission or regulatory
authority. No new shares, BTA, subscription rights or other
securities issued by Active Biotech have been or will be registered
under the U.S. Securities Act of 1933, as amended, or under the
securities legislation in any state of the United States, and may
not be offered, exercised or sold in the United States absent
registration or an applicable exemption from registration
requirements. There is no intention to register any portion of the
rights issue in the United States or to conduct a public offering
of securities in the United States.
The Company has not
authorized any offer of the securities referred to herein to the
public in any country in the European Economic Area ("EEA") other
than Sweden. In other member states in the EEA, the securities may
only be offered to (a) any legal entity which is a qualified
investor as defined in the Directive 2003/71/EC (the "Prospectus
Directive"); or (b) any person falling within Article 3(2) of the
Prospectus Directive.
In the
United Kingdom, this communication is only being distributed to,
and is only directed at "qualified investors" (as defined in
section 86(7) of the Financial Services and Markets Act 2000) who
are (i) investment professionals falling within the meaning of
Article 19(5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005 (the "Order"); or (ii) persons
falling within Article 49(2)(a) to (d) ("high net worth companies,
unincorporated associations, etc.") of the Order (all such persons
together being referred to as "relevant persons"). In the United
Kingdom, any investment or investment activity to which this
communication relates is available only to, and will be engaged in
only with, relevant persons. Any person who is not a relevant
person should not take any action on the basis of this
communication and should not act or rely on it or any of its
contents.
161118_Prospectus relating to
Active Biotech's rights issue published
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2023 to Mar 2024